Screener / SEC EDGAR /CIK 0001601830 /10-K filed Feb 25, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Recursion Pharmaceuticals, Inc. RXRX

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of RXRX's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter May 30, 2024
Questions asked 34 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 34 numbered comments
  3. 3. Company replies 1 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 14 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2023

2024-05-30 to 2024-06-13 · 5 questions · 1 letter from the SEC, 0 from the company
Review closed 2024-06-13
Results discussion (MD&A)RevenueControls
SEC letter of May 30, 2024 ↗ no reply letter on EDGAR
Management's Discussion and Analysis of Financial Condition and Results of Operations · Partnerships, page 154
SEC asked (1)
You state throughout the filing that you entered into a collaboration agreement with Enamine in December 2023 to generate and design enriched compound libraries for the global drug discovery industry. Please tell us the terms of the agreement, the accounting treatment thereof, and why additional disclosure is not required in the filing, including the financial statements.
RXRX answered

No reply letter found.

In its next report

First report after the SEC's letter of May 30, 2024: 10-Q filed Aug 8, 2024 ↗, against the 10-Q filed May 9, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Research and Development, page 157
SEC asked (2)
Please confirm to us that the $22.0 million upfront payment for the Tempus agreement, which as disclosed on page 149 was paid with the issuance of 3.2 million shares, was recorded in research and development expense. Confirm to us that you will disclose your accounting policy applicable to such upfront payments in future filings or direct us to existing disclosure.
Rest of the question

Also, please clarify to us, and in future filings, what line item the payments made in connection with the Tempus agreement are included in the table on page 157 and why.

RXRX answered

No reply letter found.

In its next report

First report after the SEC's letter of May 30, 2024: 10-Q filed Aug 8, 2024 ↗, against the 10-Q filed May 9, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Consolidated Financial Statements · Consolidated Statements of Convertible Preferred Stock and Stockholders Equity, page 171
SEC asked (3)
In future filings, please correct the label Comprehensive Loss to reflect that Net Loss and not Comprehensive Loss is added to Accumulated Deficit in all periods presented, or tell us why your current presentation is adequate.
RXRX answered

No reply letter found.

In its next report

First report after the SEC's letter of May 30, 2024: 10-Q filed Aug 8, 2024 ↗, against the 10-Q filed May 9, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 8. Common Stock · NVIDIA Private Placement, page 185
SEC asked (4)
You disclose on page 69 that in July 2023 you entered into a collaboration agreement with NVIDIA to accelerate the development of your groundbreaking AI foundation models for biology and chemistry using your supercomputer, BioHive-1, and priority access on NVIDIA DGX™ Cloud.
Rest of the question

Please tell us the following: • the terms of the collaboration agreement, the accounting treatment thereof, and why disclosure is not required in the filing, including the financial statements, and • why none of the proceeds from the NVIDIA private placement are required to be allocated to the concurrent collaboration agreement under ASC 606-10-25-9.

RXRX answered

No reply letter found.

In its next report

First report after the SEC's letter of May 30, 2024: 10-Q filed Aug 8, 2024 ↗, against the 10-Q filed May 9, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9A. Controls and Procedures · Management's Annual Report on Internal Control over Financial Reporting, page 196
SEC asked (5)
In future filings on Form 10-K, please specifically state whether your internal controls over financial reporting are effective at the end of the reporting period. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
RXRX answered

No reply letter found.

In its next report

First report after the SEC's letter of May 30, 2024: 10-Q filed Aug 8, 2024 ↗, against the 10-Q filed May 9, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-06-13

Form S-1

2021-02-22 to 2021-03-22 · 29 questions · 2 letters from the SEC, 1 from the company
No closing letter
Risk factorsSegmentsLiquidity and cashDebtResults discussion (MD&A)Critical estimates
SEC letter of Feb 22, 2021 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Overview, page 1
SEC asked (1)
We note your disclosure here and throughout the prospectus that you use your technology to "rapidly accelerate" programs, that your strategy is to "rapidly advance" your Notable Products through development and potential regulatory submission, that wet-lab biology and in silico tools "accelerates" your drug discovery process, that you "identify low-viability programs earlier in the research cycle," "spend less per
Rest of the question

program" because of your approach, and "advance programs more quickly from program start to the clinic" compared to industry averages, and that you "expect to continue accelerating the pace of program additions in the future." Please balance this disclosure and similar disclosure throughout the prospectus to clarify that the process of clinical development is inherently uncertain and that there can be no guarantee that you will achieve similar development timelines with your future product candidates. Please also revise this disclosure and similar disclosure throughout the prospectus to remove any implication that you will be successful in obtaining regulatory approval or commercializing your product candidates in a rapid or accelerated manner as such statements are speculative. Prospectus Summary, page 1

RXRX answered

No reply letter found.

Overview, page 1
SEC asked (2)
We note the use of the term "rescue" in this section and throughout the prospectus. To the extent that you are using this term to imply that the use of your proprietary technology on data from previous trials performed by other parties has resolved issues relating to safety and/or efficacy and will ultimately lead to the approval of your product candidates, please revise your registration statement to eliminate the
Rest of the question

use of this term. You may disclose that administration of a product candidate was well tolerated or resulted in no serious adverse events and provide a discussion of prior trial results. However, it is not appropriate to imply that the use of your proprietary technology on data from previous trials performed by other parties has resolved issues relating to safety and/or efficacy and will ultimately lead to the approval of your product candidates. If you choose to say that the product candidates were well tolerated in previous clinical trials or that there were no serious adverse events or discuss prior clinical results, please clarify that prior results are not necessarily predictive of the outcome of future trials. If you are intending to assign a different meaning to the term "rescue" than discussed above, please make that clear throughout the prospectus.

RXRX answered

No reply letter found.

The Recursion OS, page 5
SEC asked (3)
We note your disclosure that your core dataset is based on images of cells, that you use cell morphology to understand how a diseased cell responds to drugs and that your PhenoMap tooling enables you to explore inferred biological and chemical relations in order to "deconvolve" mechanisms of action. We also note that that the two programs based on your inferential search approach are in the discovery stage.
Rest of the question

Please briefly indicate how your inferential search programs allow you to "deconvolve" mechanisms of action, provide a definition of that term, and discuss any material efforts you would need to take in order to further understand the mechanism of action of any drug candidate before you would proceed to clinical trials with that candidate. In this regard, we note your disclosure on page 177 under "Predicting the Mechanism of Action" that further understanding the mechanism by which compounds are operating is traditionally the "Achilles heel" of phenotypic drug discovery and your disclosure under "Orthogonomics" on page 163 that other data modalities such as transcriptomics and proteomics can be highly complementary to phenomics but that both of those approaches are "orders of magnitude" more expensive compared to phenomics. Given this disclosure, please ensure that your prospectus summary briefly indicates the material challenges that your inferential search approach presents to moving drug candidates into clinical trials, including any challenges to obtaining IND approval if the mechanism of action is not understood, and that your prospectus summary presents balanced disclosure in this regard.

RXRX answered

No reply letter found.

Brute-Force Search Programs, page 7
SEC asked (4)
Please remove the references on page 8 and throughout the prospectus to the potential for certain of your lead molecules to be first-in-disease. This disclosure suggests that your product candidates will be effective and will be approved before any other product candidate for these indications, which is not appropriate given the current stage of development.
Rest of the question

You may state that there are currently no approved therapies for these indications, if true.

RXRX answered

No reply letter found.

Our Pipeline, page 7
SEC asked (5)
Please revise your pipeline table to include a column for Phase 3. Please also provide only one column for the discovery phase. The length of the line within the discovery phase will visually demonstrate whether the product candidate is early-stage or late-stage in the discovery process, and a textual discussion of the program is a more appropriate place to make distinctions regarding different segments within a
Rest of the question

particular phase. We note that you have five programs for which you have yet to select a compound that will be the focus of further development. Please explain to us why each of those programs is sufficiently material to your business to warrant inclusion in your pipeline table or revise your table as appropriate.

RXRX answered

No reply letter found.

Inferential Search Programs, page 9
SEC asked (6)
We note that you have included a separate table depicting 25 additional programs. We also note that your filing only includes a discussion of the two programs in this table that are in the preclinical phase, which implies that the other programs are not sufficiently material to your operations to warrant discussion. Please delete the references to these other programs from the Prospectus Summary.
RXRX answered

No reply letter found.

Our Partnerships, page 10
SEC asked (7)
Please remove the references throughout your prospectus to potential "first-in-class" or "best-in-class" product candidates as these descriptions imply an expectation of regulatory approval and are inappropriate given the length of time and uncertainty with respect to securing marketing approval.
RXRX answered

No reply letter found.

Risk Factors, page 22
SEC asked (8)
Given the length of your risk factor section, please revise to comply with Regulation S-K Item 105 by relocating risks that could generically apply to any registrant or offering to the end of the section under the caption "General Risk Factors." Our amended and restated bylaws that will become effective upon the closing of this offering,
RXRX answered

No reply letter found.

Risk Factors, page 22
SEC asked (9)
Please revise this risk factor to disclose that there is also a risk that your exclusive forum provision may result in increased costs for investors to bring a claim. Use of Proceeds, page 96
RXRX answered

No reply letter found.

Risk Factors, page 22
SEC asked (10)
Please disclose how far you expect the proceeds from the offering to allow you to proceed in the development of each of your programs. We note your disclosure that you intend to paydown debt with some of the proceeds of this offering. Please disclose the interest rate and maturity of such indebtedness.
Rest of the question

If the indebtedness to be discharged was incurred within one year, describe the use of the proceeds of such indebtedness other than shortterm borrowings used for working capital. See Instruction 4 to Rule 504 of Regulation S- K.

RXRX answered

No reply letter found.

Management's Discussion and Analysis of Financial Condition and Results of Operations, page · 106
SEC asked (11)
Tell us and revise to clarify the extent to which you track your research and development expense by program or product candidate. If available, provide a breakdown of your research and development expenses by program or product candidate, as well as a breakdown of research and development expenses by nature of expense.
RXRX answered

No reply letter found.

Critical Accounting Policies and Use of Estimates · Determination of Fair Value of Common Stock, page 120
SEC asked (12)
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the initial public offering and the estimated offering price.
Rest of the question

This information will help facilitate our review of your accounting for equity issuances including stock compensation and beneficial conversion features. Please discuss with the staff how to submit your response.

RXRX answered

No reply letter found.

Business · FreshCuts, page 157
SEC asked (13)
We note your disclosure in Table 3 that FreshCuts exceeds state-of-the-art vendor library design algorithms. Please explain what makes the vendor algorithms "state-of-the-art" and how you determined that FreshCuts exceeds them. Please also tell us why you believe this disclosure is material to an understanding of your business.
RXRX answered

No reply letter found.

REC-4881: Familial Adenomatous Polyposis · Clinical, page 189
SEC asked (14)
Please provide the basis for your statement that REC-4881 demonstrated a favorable ocular safety profile compared to approved drugs in this class.
RXRX answered

No reply letter found.

Patents, page 222
SEC asked (15)
Please revise to disclose the material foreign jurisdictions where you own or license patents or pending patent applications.
RXRX answered

No reply letter found.

Compound IP, page 223
SEC asked (16)
Please revise to disclose the type of patent protection that you have (composition of matter, use or process).
RXRX answered

No reply letter found.

Bayer, page 240
SEC asked (17)
We note your disclosure that you have not entered into any lead series or development candidate license agreements with Bayer yet and that you would receive an option exercise fee, with the potential to receive further development and commercial milestones of more than $100 million as well as tiered royalties under each such license agreement.
Rest of the question

To the extent that these terms have already been set forth in the current agreement, please revise to disclose the amount of the option exercise fee, the maximum aggregate development and commercial milestones that you would be eligible to receive for each development candidate, the royalty range and the royalty term. Please also revise to disclose the termination provisions of the current agreement and when the term of the current agreement ends.

RXRX answered

No reply letter found.

Sanofi-Genzyme, page 241
SEC asked (18)
Please revise to disclose the payment provisions under the agreement such as the aggregate amounts paid or received to date, the termination provisions and the term of the agreement. Please also disclose how you would be compensated if Sanofi-Genzyme exercises its option to develop any products.
RXRX answered

No reply letter found.

General
SEC asked (19)
In the letter from the CEO, we note your statement on page 4 that you are "leaders in this space." Please explain to us the basis for this claim; we note that your most advanced product candidates have completed Phase 1 clinical trials and that you have not yet obtained regulatory approval for a product candidate.
Rest of the question

Please substantiate your claims here that you have "one of the largest proprietary biological datasets on earth" and "one of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company," and your claims on page 143 that you have "one of the largest biological and chemical datasets" and on page 146 that you have curated "one of the most comprehensive KCE libraries in the world."

RXRX answered

No reply letter found.

General
SEC asked (20)
A registration statement is not intended to serve as marketing materials. Therefore, the prominence of the graphics on certain pages leading up to the letter from the co-founder and CEO and in Figures 14-16, 18-23, 31-35 and 75-77 is not appropriate because the graphics neither provide nor enhance relevant and meaningful disclosure that investors can use to make an informed investment decision.
Rest of the question

In particular, the second page of graphics before the CEO letter repeats information already contained in the Prospectus Summary and Business sections. Please remove these graphics accordingly.

RXRX answered

No reply letter found.

General
SEC asked (21)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
RXRX answered

No reply letter found.

Prospectus Summary · Overview, page 1
SEC asked (1)
We note your revisions in response to prior comment 1 and reissue. Please revise the first paragraph in this section to state that there is no guarantee that you will achieve similar development timelines with your future product candidates.
Rest of the question

Please revise the statements on pages 141 and 216 that your strategy is to "rapidly" advance your Notable Products through development and toward regulatory submission and similar disclosure throughout the prospectus to remove any implication that you will be successful in obtaining regulatory approval or commercializing your product candidates in a rapid or accelerated manner as such statements are speculative. Please balance the disclosure on page 131 that you “identify low-viability programs earlier in the research cycle,” “spend less per program” because of your approach, and “advance programs more quickly from program start to the clinic” compared to industry averages to state that the process of clinical development is inherently uncertain and there can be no guarantee that you will achieve similar development timelines with your future product candidates.

RXRX answered
to the Staff’s comment, the Company has made numerous changes throughout the prospectus. Thus, the Company updated the disclosures on pages 1, 4, 10, 109, 128, 132, 133, 143 and 218 to state that the Company cannot provide any guarantee that it will achieve similar development timelines with its future product candidates.
Rest of the answer

The Company also updated the disclosures on pages 5, 10, 133, 143 and 218 to clarify that, despite the Company’s strategy to “rapidly” advance its Notable Products through development and toward regulatory submission, the Company may not be successful in obtaining regulatory approval or commercializing its product candidates on an accelerated basis, or at all. The Company has further updated the disclosure on page 133 of the Registration Statement to qualify the disclosure that the Company will

“identify low-viability programs earlier in the research cycle,” will “spend less per program” because of the Company’s approach, and will “advance programs more quickly from program start to the clinic” compared to industry averages by stating that the Company only believes its Recursion OS will be able to achieve in these areas, but the Company can provide no guarantee that it will achieve similar development timelines with future product candidates.

Read in the reply
The Recursion OS, page 5
SEC asked (2)
We note your response to prior comment 3 and reissue in part. Please revise your Prospectus Summary to indicate the material challenges that your inferential search approach presents to moving drug candidates into clinical trials, including any challenges to obtaining IND approval if the mechanism of action is not understood, and ensure that your Prospectus Summary presents balanced disclosure in this regard.
RXRX answered
to the Staff’s comment, the

Company has updated the disclosure on pages 5 and 134 to indicate that the Company’s inferential search approach may present material challenges to moving product candidates into clinical trials, including potential challenges to obtaining

IND approval if the mechanism of action is not understood, and emphasizing that the Company may not be successful in obtaining regulatory approval or commercializing its product candidates on an accelerated basis, or at all.
Read in the reply
Influential Search Programs, page 9
SEC asked (3)
We note your response to prior comment 6 regarding the table on page 10 depicting 25 additional programs. Please provide us with further analysis as to why these additional programs are sufficiently material to investors for inclusion in the prospectus summary and as to how your current disclosure presents balanced disclosure given that you have not specified the disease genes or compounds being studied, and the
Rest of the question

currently disclosed therapeutic areas may be overly broad, or revise your disclosure as appropriate. Class B common stock to be outstanding immediately after this offering, page 14

RXRX answered
The Company acknowledges the Staff’s comment and has removed the table referred to on page 9 of the prospectus summary for the

Registration Statement to deemphasize the 27 programs that are in the early stages of development and has included additional text to further explain the relevance and importance of these additional programs as a material element of the

Company’s value proposition.
Read in the reply
Influential Search Programs, page 9
SEC asked (4)
We note that the second to last bullet point on page 15 only addresses the shares of Class A common stock that are reserved for issuance under you 2021 Plan. However, your disclosure on page 260 currently indicates that Class A and Class B shares will be reserved for issuance under that plan. If Class B shares will be reserved for issuance under the 2021 Plan, please revise your bullet point as appropriate.
Rest of the question

Risks Related to Our Class A Common Stock and This Offering The dual-class structure of our common stock will have the effect of concentrating voting power,

RXRX answered
to the

Staff’s comment, the Company has revised the bullet point on pages 15, 101 and 105 of the Registration Statement to remove the reference to the reservation of Class B shares under the 2021 Plan. Only shares of Class A common stock will be reserved for issuance under the 2021 Plan.
Read in the reply
Influential Search Programs, page 9
SEC asked (5)
If appropriate, please revise this risk factor to disclose that future issuances of your Class B common stock as well as mandatory and optional conversions of your Class B common stock may be dilutive to holders of your Class A common stock.
Rest of the question

Please also disclose the percentage of outstanding shares that Class B shareholders must maintain to continue to control the outcome of matters submitted to shareholders for approval. Use of Proceeds, page 97

RXRX answered
to the Staff’s comment, the Company has revised the risk factor referenced above to disclose that planned future issuances of Class B common stock as well as mandatory and optional conversions of such Class B common stock may be dilutive to holders of our Class A common stock. Following further development of the dual-class structure, only Christopher Gibson, Ph.D., co-founder and Chief Executive Officer of the Company, will hold shares of Class B common stock.
Rest of the answer

Based on 85,629,895 shares of the

Company’s Class A common stock (after giving effect to the conversion of all of shares of convertible preferred stock) and 6,311,922 shares of the Company’s Class B common stock (after giving effect to the exchange of shares of Class A common stock for an equivalent number of shares of Class B common stock by Dr. Gibson) outstanding as of December 31, 2020, Dr. Gibson would hold 42.4% of the voting power of the Company, which percentage is expected to decrease as a result of issuances in the offering. As such, he will have significant influence on, but will not control the outcome of, matters submitted to shareholders for approval. Under the terms of the amended and restated certificate of incorporation expected to be effective upon completion of the offering, Dr. Gibson will be able to exchange a maximum of 1,000,000 shares of Class A common stock issuable upon exercise of outstanding options as such options vest, but the additional shares of Class B common stock held following such exchanges would amount to less than 50% of the voting power of the Company prior to the issuance of any shares in the offering.

Read in the reply
Influential Search Programs, page 9
SEC asked (6)
We note your revisions in response to prior comment 10. Please revise to disclose how many product candidates you expect to be able to move from hit screening through hit identification, hit identification through identification of development candidates and identification of development candidates through commercialization using the proceeds of this offering.
Rest of the question

Please remove the reference to "commercialization" if you do not believe that you will be able to fund any product candidates through commercialization using the proceeds and specify what stage of clinical development you expect to reach with the proceeds. For example, will you be advancing your product candidates that have completed Phase 1 clinical trials into Phase 2 trials using the proceeds of this offering and, if so, will you be able to complete those Phase 2 trials with the proceeds or will you be able to complete human proof of concept trials for a certain number of product candidates?

RXRX answered
to the Staff’s comment, the Company has revised the disclosure related to use of proceeds from the offering on page 97 of the Registration Statement to remove the reference to commercialization, because the Company does not know if there will be any proceeds from the offering remaining to use for commercializing any of its product candidates nor whether any such candidates will reach commercialization, and may decide to partner with third parties to commercialize its product candidates should they reach this stage.
Rest of the answer

In addition, the Company cannot predict with accuracy the number of programs it will be able to progress through each of the categories of expenditures the Company had proposed in the Draft Registration Statement. As a result, the Company has revised the disclosure on page 97 of the Registration Statement to indicate the use of proceeds is expected to be focused on its Notable Programs. The Company has separated its 10 Notable Programs into two categories, clinical and pre-clinical, and plans to indicate in a subsequent amendment to the Registration Statement the amount of proceeds the Company expects to use to advance these programs.

Read in the reply
Business · Bayer, page 239
SEC asked (7)
We note your revisions in response to prior comment 17. Please revise to clarify whether the royalty term is the same as the term of the license agreement.
RXRX answered
to the Staff’s comment, the Company has revised the disclosure on page 241 of the Registration Statement to clarify that royalty periods under the Bayer Agreement for each license are on a country-by-country basis, and the duration of each such period is tied to the duration of patent or regulatory exclusivity in each country (with a minimum term of

10 years each).
Read in the reply
General
SEC asked (8)
We note your response to prior comment 19. Please revise the statement that you are among the leaders in the space to briefly disclose the basis for the statement as described in your response or revise your leadership statement as appropriate.
RXRX answered
to the Staff’s comment, the Company has revised the disclosure on page 4 of the Registration Statement to instead state, as evidenced in the cited articles, that the Company has been recognized as one of the most established artificial intelligence drug discovery companies1 and a major player in the nascent field of artificial intelligence-focused drug discovery.2

*****

See Recursion Pharmaceuticals Raises $239 Million and Partners with Bayer for AI Drug Discovery, Forbes

September 2020, available at
Rest of the answer

https://www.forbes.com/sites/leahrosenbaum/2020/09/09/recursion-pharmaceuticals-raises-239-million-and-partners-with-bayer-for-ai-drug-discovery/?

sh=81a516224165

See Recursion nabs $239M and an up to $1B partnership with Bayer as AI race heats up, Endpoint News,

September 9, 2020, available at https://endpts.com/recursion-nabs-239m-and-an-up-to-1b-partnership-with-bayer-as-ai-race-heats-up/

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
3 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 8 letters filed since 2021-02-22. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RXRX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.